ERS/ATS technical standard on interpretive strategies for routine lung function tests
- PMID: 34949706
- DOI: 10.1183/13993003.01499-2021
ERS/ATS technical standard on interpretive strategies for routine lung function tests
Abstract
Background: Appropriate interpretation of pulmonary function tests (PFTs) involves the classification of observed values as within/outside the normal range based on a reference population of healthy individuals, integrating knowledge of physiological determinants of test results into functional classifications and integrating patterns with other clinical data to estimate prognosis. In 2005, the American Thoracic Society (ATS) and European Respiratory Society (ERS) jointly adopted technical standards for the interpretation of PFTs. We aimed to update the 2005 recommendations and incorporate evidence from recent literature to establish new standards for PFT interpretation.
Methods: This technical standards document was developed by an international joint Task Force, appointed by the ERS/ATS with multidisciplinary expertise in conducting and interpreting PFTs and developing international standards. A comprehensive literature review was conducted and published evidence was reviewed.
Results: Recommendations for the choice of reference equations and limits of normal of the healthy population to identify individuals with unusually low or high results are discussed. Interpretation strategies for bronchodilator responsiveness testing, limits of natural changes over time and severity are also updated. Interpretation of measurements made by spirometry, lung volumes and gas transfer are described as they relate to underlying pathophysiology with updated classification protocols of common impairments.
Conclusions: Interpretation of PFTs must be complemented with clinical expertise and consideration of the inherent biological variability of the test and the uncertainty of the test result to ensure appropriate interpretation of an individual's lung function measurements.
The content of this work is not subject to copyright. Design and branding are copyright ©ERS 2022. For reproduction rights and permissions contact permissions@ersnet.org.
Conflict of interest statement
Conflict of interest: S. Stanojevic reports grants, support for travel from the European Respiratory Society and was the Co-Chair of the Global Lung Function Initiative for the European Respiratory Society; and additionally acted on the Pulmonary Function Testing Proficiency committee for the American Thoracic Society, all outside the submitted work. Conflict of interest: D.A. Kaminsky reports speaker fees from MGC Diagnostics, Inc. and honoraria from UpToDate, Inc., outside the submitted work. Conflict of interest: M.R. Miller has nothing to disclose. Conflict of interest: B. Thompson reports grants from the NHMRC; consulting fees from 4D Medical and Chiesi; lecture honoraria from 4D Medical, Chiesi and Mundipharma; and reports past academic work with the Global Lung Function Initiative for the European Respiratory Society, outside the submitted work. Conflict of interest: A. Aliverti reports patents on Forced Oscillation Technique from Philips and patents on Opto-Electronic Plethysmography from BTS Bioengineering, outside the submitted work. Conflict of interest: I. Barjaktarevic has nothing to disclose. Conflict of interest: B.G. Cooper acted as Co-Chair of the Global Lung Function Initiative at the European Respiratory Society, outside the submitted work. Conflict of interest: B. Culver has nothing to disclose. Conflict of interest: E. Derom has nothing to disclose. Conflict of interest: G.L. Hall was former Co-Chair of the Global Lung Function Initiative and reports previous academic and leadership work with the Global Lung Function Initiative, both with the European Respiratory Society, outside the submitted work. Conflict of interest: T.S. Hallstrand reports research grants from the NIH (NHLBI, NIAID), outside the submitted work. Conflict of interest: J.D. Leuppi reports grants from the Swiss National Science Foundation (SNF 160072 and 185592) and Swiss Personalised Health Network (SPHN 2018DR108); and has also received unrestricted grants from AstraZeneca AG Switzerland, Boehringer Ingelheim GmbH Switzerland, GSK AG Switzerland and Novartis AG Switzerland, outside the submitted work. Conflict of interest: N. MacIntyre reports consulting fees from Vyaire, outside the submitted work. Conflict of interest: M. McCormack reports royalties for authorship for PFT chapters from UpToDate; consulting fees related to PFT quality and reading from Aridis, outside the submitted work. Conflict of interest: M. Rosenfeld has nothing to disclose. Conflict of interest: E.R. Swenson has nothing to disclose.
Comment in
-
The new ERS/ATS standards on lung function test interpretation: some extant limitations.Eur Respir J. 2022 Aug 10;60(2):2200252. doi: 10.1183/13993003.00252-2022. Print 2022 Aug. Eur Respir J. 2022. PMID: 35487532 No abstract available.
-
Reply: The new ERS/ATS standards on lung function test interpretation: some extant limitations.Eur Respir J. 2022 Aug 10;60(2):2201112. doi: 10.1183/13993003.01112-2022. Print 2022 Aug. Eur Respir J. 2022. PMID: 35777772 No abstract available.
-
Pulmonary function interpretative strategies: from statistics to clinical practice.Eur Respir J. 2022 Jul 13;60(1):2200317. doi: 10.1183/13993003.00317-2022. Print 2022 Jul. Eur Respir J. 2022. PMID: 35835474 No abstract available.
-
A reply to questions raised about FEV1Q and bronchodilator responsiveness.Eur Respir J. 2023 Jan 19;61(1):2202025. doi: 10.1183/13993003.02025-2022. Print 2023 Jan. Eur Respir J. 2023. PMID: 36549704 Free PMC article.
-
A query on FEV1Q: it may be useful, but is it helpful?Eur Respir J. 2023 Jan 19;61(1):2201646. doi: 10.1183/13993003.01646-2022. Print 2023 Jan. Eur Respir J. 2023. PMID: 36549707 No abstract available.
-
Improving pulmonary function test interpretation.Eur Respir J. 2023 Jan 19;61(1):2201858. doi: 10.1183/13993003.01858-2022. Print 2023 Jan. Eur Respir J. 2023. PMID: 36549709 No abstract available.
-
Reply: The puzzles of lung function interpretation.Eur Respir J. 2023 Feb 16;61(2):2202444. doi: 10.1183/13993003.02444-2022. Print 2023 Feb. Eur Respir J. 2023. PMID: 36796849 No abstract available.
-
The puzzles of lung function interpretation.Eur Respir J. 2023 Feb 16;61(2):2202070. doi: 10.1183/13993003.02070-2022. Print 2023 Feb. Eur Respir J. 2023. PMID: 36796851 No abstract available.
-
ERS/ATS spirometry interpretation standards: a gap in grading severity of airflow obstruction.Eur Respir J. 2024 Feb 1;63(2):2301910. doi: 10.1183/13993003.01910-2023. Print 2024 Feb. Eur Respir J. 2024. PMID: 38302181 Free PMC article. No abstract available.
Similar articles
-
How to interpret parameters of routine lung function tests in 2023?Tunis Med. 2023 Mar 5;101(3):323-333. Tunis Med. 2023. PMID: 38263920 Free PMC article. French.
-
Routine pulmonary lung function tests: Interpretative strategies and challenges.Chron Respir Dis. 2024 Jan-Dec;21:14799731241307252. doi: 10.1177/14799731241307252. Chron Respir Dis. 2024. PMID: 39644209 Free PMC article. Review.
-
Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement.Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88. doi: 10.1164/rccm.201908-1590ST. Am J Respir Crit Care Med. 2019. PMID: 31613151 Free PMC article.
-
[Standardization of spirometry updated in China and international: comparison and interpretation of the key updates].Zhonghua Jie He He Hu Xi Za Zhi. 2022 Mar 12;45(3):250-254. doi: 10.3760/cma.j.cn112147-20210412-00244. Zhonghua Jie He He Hu Xi Za Zhi. 2022. PMID: 35279987 Chinese.
-
The Evolving Role of Pulmonary Function Interpretation: Clinical Implications of the New ERS/ATS Standards in Asthma Care.J Investig Allergol Clin Immunol. 2025 Apr 22;35(2):76-86. doi: 10.18176/jiaci.1084. Epub 2025 Mar 14. J Investig Allergol Clin Immunol. 2025. PMID: 40084848 Review.
Cited by
-
Bronchial asthma with normal forced expiratory volume in 1 second (FEV1) compared with low FEV1.J Thorac Dis. 2024 Sep 30;16(9):5580-5590. doi: 10.21037/jtd-24-868. Epub 2024 Aug 30. J Thorac Dis. 2024. PMID: 39444879 Free PMC article.
-
Diffusing capacity as an independent predictor of acute exacerbations in chronic obstructive pulmonary disease.Sci Rep. 2024 Feb 5;14(1):2936. doi: 10.1038/s41598-024-51593-8. Sci Rep. 2024. PMID: 38316813 Free PMC article.
-
A comparative study of bronchodilator response: utilizing pre-bronchodilator versus predicted normal values.BMC Pulm Med. 2024 Jan 25;24(1):54. doi: 10.1186/s12890-024-02859-4. BMC Pulm Med. 2024. PMID: 38273287 Free PMC article.
-
Hypercapnia and lung function parameters in chronic obstructive pulmonary disease.BMC Pulm Med. 2024 Jul 16;24(1):345. doi: 10.1186/s12890-024-03151-1. BMC Pulm Med. 2024. PMID: 39014325 Free PMC article.
-
How to account for Inuit ancestry in lung function prediction.Int J Circumpolar Health. 2023 Dec;82(1):2151158. doi: 10.1080/22423982.2022.2151158. Int J Circumpolar Health. 2023. PMID: 36471626 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical